Dr. Gregory Gutierrez is a senior associate in Goodwin’s Life Sciences group.
Greg advises companies and investors on patent matters for life sciences and chemical innovations. He leverages his background in organic chemistry to help clients develop and manage global patent portfolios for their therapeutic products across all stages of clinical development, as well as after regulatory approval. He also supports clients during IP due diligence for various types of transactions, including M&A, venture financings, strategic partnerships, and public offerings.
Experience
Greg partners with life sciences companies of different sizes to build robust and valuable portfolios for a variety of product candidates, including small molecules, antibody-drug conjugates, peptides, biomaterials, and oligonucleotides. This encompasses patent protection for both composition of matter and next-generation inventions arising during product development, including course of treatment, solid forms/polymorphs, and drug product formulations. Greg is experienced in optimizing the exclusivities of FDA-approved products in anticipation of generic competition, including through patent term extension and Orange Book patent strategy. With respect to licensed assets, Greg often advises clients of their rights and obligations under the intellectual property provisions of license agreements.
Greg was previously a science advisor and law clerk at Goodwin. Prior to joining Goodwin, Greg was a technology specialist at an intellectual property-focused law firm in the Boston area.
Representative Matters
- Deciphera Pharmaceuticals on its global patent strategy, including for its marketed products QINLOCK® (ripretinib) and ROMVIMZA™ (vimseltinib).
- Alkermes on its patent term extension and Orange Book patent strategies for LYBALVI® (samidorphan and olanzapine).
- Advising early- and clinical-stage companies on global patent strategy for their platform technologies and clinical candidates, including patent drafting, US and ex-US prosecution, and evaluating of freedom to operate.
- Successfully conducted ex parte appeal proceedings before the USPTO Patent Trial and Appeal Board (PTAB) to reverse all rejections in a patent application on behalf of a clinical-stage biomaterials company, including appearance as counsel in oral argument.
- Deciphera Pharmaceuticals on patent matters relating to its $2.4 billion acquisition by ONO Pharmaceutical.
- MorphImmune on patent matters related to its merger with Immunome.
- IP due diligence on behalf of a venture capital firm in connection with its investments in various portfolio companies, including Iambic Therapeutics, Cardurion Pharmaceuticals, OrsoBio, Odyssey Therapeutics, Alpha-9 Oncology, and Triana Biomedicines.
- Fulcrum Therapeutics on IP matters relating to various public offerings.
Credentials
Education
JD2021
Suffolk University Law School
PhDOrganic Chemistry2016
Massachusetts Institute of Technology
BAChemistry2011
Cornell University
Admissions
Bars
- California
- Massachusetts
- U.S. Patent and Trademark Office (USPTO)
Publications
- Co-author, “Patents and intellectual property in drug discovery,” Reference Module in Chemistry, Molecular Sciences and Chemical Engineering, Elsevier, 2025.
- Co-author, “The Federal Circuit Raises the Section 112 Stakes for Chemical Structures in Seagen v. Daiichi,” Goodwin Alert, December 2025.
- Author, “PTAB Issues Final Written Decision Finding Seagen Antibody-Drug Conjugate Patent Claims to be Unpatentable,” Life Sciences Perspectives, January 2024.